Save time and get answers to complex questions with AI chat
Dabrafenib patent expiration date novartis gsk composition matter?When will generic fiasap insulin be available?Campath litigation germany?What's the recommended schedule for lurbinectedin side effect checks?Complera manufacturer?
See the DrugPatentWatch profile for Rinvoq
Rinvoq (upadacitinib) was first approved in the U.S. on August 29, 2019, for adults with moderate-to-severe rheumatoid arthritis. It launched commercially in the U.S. shortly after that approval (fall 2019). If you meant launch date for another country or for a different indication, tell me the country/indication and I’ll look up the specifics.
Other Questions About Rinvoq :